Study 12626. Chiu P, Huang W, Huang S, Chih Y, Chen C. Program Errors in Taiwan’s mass immunizations against pandemic A/H1N1. Taiwan Centers Dis Control. 2010;26(15):268-75. (2010) |
China |
Epidemiological, descriptive LE*= VI |
Determine types of errors and assess critical contributors to the error |
11/2009 to 02/2010 |
General population vaccinated with H1N1 |
Study 22424. Moro PL, Harrington T, Shimabukuro T, Cano M, Museru OI, Menschik D, et al. Adverse events after Fluzone® Intradermal vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2011-2013. Vaccine . 2013;31(43):4984-7. doi: https://doi.org/10.1016/j.vaccine.2013.08.001 https://doi.org/10.1016/j.vaccine.2013.0...
(2013) |
United States |
Epidemiological, descriptive LE*=VI |
Characterize ESAVI† after administration of the trivalent intradermal inactivated influenza vaccine reported to the United States Adverse Event Reporting System (VAERS‡) |
07/2011 to 02/2013 |
Population vaccinated with Fluzone Intradermal vaccine |
Study 32323. Moro PL, Winiecki S, Lewis P, Shimabukuro TT, Cano M. Surveillance of adverse events after the first trivalent inactivated influenza vaccine produced in mammalian cell culture (Flucelvax®) reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015. Vaccine . 2015;33(48):6684-8. doi: https://doi.org/10.1016/j.vaccine.2015.10.084 https://doi.org/10.1016/j.vaccine.2015.1...
(2015) |
United States |
Epidemiological, descriptive LE*=VI |
Evaluate adverse events following administration of trivalent subunit inactivated influenza vaccine reported to the United States Adverse Event Reporting System (VAERS‡) |
07/2013 to 03/2015 |
General population vaccinated with Flucevax |
Study 466. Bisetto LHL, Ciosak SI. Analysis of adverse events following immunization caused by immunization errors. Rev Bras Enferm. 2017;70(1):87-95. doi: https://doi.org/10.1590/0034-7167-2016-0034 https://doi.org/10.1590/0034-7167-2016-0...
(2017) |
Brazil |
Cross-sectional, descriptive LE*=VI |
Analyze the occurrence of ESAVI† resulting from immunization errors, in Paraná, from 2003 to 2013 |
01/2003 to 12/2013 |
General population vaccinated in Paraná |
Study 588. Braga PCV, Silva AEBC, Mochizuki LB, Lima JC, Sousa MRG, Bezerra ALQ. Incidence of post-vaccination adverse events in children. J Nurs UFPE on line. 2017;11(Suppl 10):4126-35. doi: https://doi.org/10.5205/1981-8963-v11i10a231174p4126-4135-2017 https://doi.org/10.5205/1981-8963-v11i10...
(2017) |
Brazil |
Cross-sectional, descriptive LE*=VI |
Analyze ESAVI† occurring in children under five years of age |
07/2012 to 06/2013 |
Children under five years of age |
Study 62525. Suragh TA, Lewis P, Arana J, Mba-Jonas A, Li R, Stewart B, et al. Safety of bivalent human papillomavirus vaccine in the US vaccine adverse event reporting system (VAERS), 2009-2017. Br J Clin Pharmacol. 2018;84(12):2928-32. doi: https://doi.org/10.1111/bcp.13736 https://doi.org/10.1111/bcp.13736...
(2018) |
United States |
Epidemiological, descriptive LE*=VI |
Review reports submitted to the United States ESAVI Reporting System† (VAERS‡) following bivalent human papillomavirus vaccine from 2009 to 2017 to increase knowledge about its safety |
01/2009 to 12/2017 |
General population vaccinated with bivalent human papillomavirus vaccine |
Study 71212. Reed L, Tarini BA, Andreae MC. Vaccine administration error rates at a large academic medical center and its affiliated clinics - Familiarity matters. Vaccine. 2019;37(36):5390-6. doi: https://doi.org/10.1016/j.vaccine.2019.07.027 https://doi.org/10.1016/j.vaccine.2019.0...
(2019) |
United States |
Epidemiological, descriptive LE*=VI |
Track and describe the absolute number of vaccine administration errors and corresponding error rates over time and by patient age and vaccine type |
01/2016 to 12/2017 |
Children and teenagers from 0 to 19 years old |
Study 877. Barboza TC, Guimarães RA, Gimenes FRE, Silva AEBC. Retrospective study of immunization errors reported in an online Information System. Rev Latino Am Enfermagem. 2020;28:e3303. doi: https://doi.org/10.1590/1518-8345.3343.3303 https://doi.org/10.1590/1518-8345.3343.3...
(2020) |
Brazil |
Cross-sectional descriptive LE*=VI |
Analyze immunization errors reported in Goiás between 2014 and 2017 |
08/2014 to 12/2017 |
General population vaccinated in Goiás |
Study 92121. Santos LCB, Silva HS, Borja-Oliveira CR, Chubaci RYS, Gutierrez BAO. Eventos adversos pós-vacinação em idosos no Estado de São Paulo, Brasil, de 2015 a 2017. Cad Saude Publica. 2021;37(4):e00084820. doi: https://doi.org/10.1590/0102-311X00084820 https://doi.org/10.1590/0102-311X0008482...
(2021) |
Brazil |
Cross-sectional, descriptive LE*=VI |
Analyze the prevalence of ESAVI† in elderly people; raise reported events; identify the vaccines that caused events and verify ESAVI† and the vaccines administered that led to hospitalizations in the State of São Paulo, Brazil, in the years 2015 to 2017 |
01/2015 to 12/2017 |
Elderly vaccinated in São Paulo |
Study 101010. Silveira IO, Silva TPR, Luvisaro BMO, Silva RB, Gusmão JD, Vimieiro AM, et al. Adverse events following immunization in pregnant women from Minas Gerais. Rev Saude Publica. 2021;55:24. doi: https://doi.org/10.11606/s1518-8787.2021055002592 https://doi.org/10.11606/s1518-8787.2021...
(2021) |
Brazil |
Epidemiological, descriptive LE*=VI |
Analyze the distribution of ESAVI† in pregnant women in the state of Minas Gerais, between 2015 and 2019 |
01/2015 to 12/2019 |
Pregnant women vaccinated in Minas Gerais |
Study 112222. Silva RB, Silva TPR, Sato APS, Lana FCF, Gusmâo JD, Souza JFA, et al. Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais. Rev Saúde Pública. 2021;55:66. doi: https://doi.org/10.11606/s1518-8787.2021055003734 https://doi.org/10.11606/s1518-8787.2021...
(2021) |
Brazil |
Epidemiological, descriptive LE*=VI |
Analyze ESAVI† against SARS-CoV-2 (COVID-19§) in the state of Minas Gerais, Brazil. |
01/20/2021 to 03/05/2021 |
General population |